Hangzhou Converd Co., Ltd.
5 clinical trials · Sponsor
◉ Watch Hangzhou Converd Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. (NCT07185243) | Hangzhou Converd Co., Ltd. | 2025-06-23 |
| Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer (NCT07006077) | Hangzhou Converd Co., Ltd. | 2025-05-29 |
| Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (NCT05914376) | Hangzhou Converd Co., Ltd. | 2023-07-05 |
| Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors (NCT03472352) | Hangzhou Converd Co., Ltd. | 2018-04-01 |
| Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer (NCT03474861) | Hangzhou Converd Co., Ltd. | 2018-04-01 |
Track Hangzhou Converd Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.